Linagliptin and Mesenchymal Stem Cells: A Pilot Study
Schizophrenia
About this trial
This is an interventional basic science trial for Schizophrenia focused on measuring DPP-4 Inhibitor, Linagliptin, SDF1-α
Eligibility Criteria
Inclusion Criteria:
- Meets DSM (Diagnostic and Statistical Manual) criteria for schizophrenia.
- Considered clinically stable, and on the same dose of antipsychotic for two weeks.
- A score no greater than 3 on the PANSS (Positive and Negative Syndrome Scale) Conceptual Disorganization item.
- Not taking any medications for diabetes, or any anti-inflammatories other than occasional aspirin or acetaminophen. Not taking Clozapine.
- Age 18-45 years.
- Can be available for regular morning appointments from 8:00 am to 10:00 am, preferably on Tuesdays, Wednesdays and Thursdays.
Exclusion Criteria:
- Does not meet DSM criteria for substance abuse or dependence.
- No serious current general medical condition, such as cancer, history of stroke or myocardial infarction, tuberculosis, HIV/AIDS, hemophilia, etc.
Sites / Locations
- University of Nevada School of Medicine
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Linagliptin patients with schizophrenia
Linagliptin control group
This group will be made up of 8 participants with schizophrenia and minimal thought disorder who have been stable and taking their prescribed antipsychotics; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment.
This group will be made up of 10 control participants with no diagnosis of mental disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day.